Patients with frequently recurring genital herpes were enrolled in a double-blind placebo-controlled trial comparing 200-mg acyclovir capsules, given five or two times daily, with placebo. Of 47 placebo recipients, 44 (94 per cent) had recurrences during the 120-day treatment period, compared with 13 (29 per cent) of 45 patients treated with acyclovir five times daily and 18 of 51 (35 per cent) treated with acyclovir twice daily (P less than 0.001 for each regimen compared with placebo). The median time to the first clinical recurrence was 18 days in placebo recipients, compared with over 120 days in both acyclovir-treated groups (P less than 0.001 for both groups compared with placebo). The mean monthly recurrence rate during the medication period was 0.86 in placebo recipients, compared with 0.13 in patients treated with acyclovir five times daily and 0.14 in patients treated with acyclovir twice daily (P less than 0.001 for both groups compared with placebo). While receiving therapy, 86 of 96 acyclovir-treated patients had over a 50 per cent reduction in their pretreatment recurrence rate. Breakthrough recurrences in acyclovir recipients were of shorter duration and associated with a lower frequency of viral shedding than recurrences in placebo recipients. After medication was discontinued, the subsequent recurrence rate returned to pretreatment frequencies. Daily oral acyclovir was well tolerated. We conclude that oral acyclovir given for four months markedly reduces but does not completely prevent recurrences of genital herpes and does not influence the long-term natural history of the disease.
This article has been cited by other articles:
Cernik, C., Gallina, K., Brodell, R. T.
(2008). The Treatment of Herpes Simplex Infections: An Evidence-Based Review. Arch Intern Med
168: 1137-1144
[Abstract][Full Text]
Fife, K. H., Meng, T.-C., Ferris, D. G., Liu, P.
(2008). Effect of Resiquimod 0.01% Gel on Lesion Healing and Viral Shedding When Applied to Genital Herpes Lesions. Antimicrob. Agents Chemother.
52: 477-482
[Abstract][Full Text]
Kimberlin, D. W., Rouse, D. J.
(2004). Genital Herpes. NEJM
350: 1970-1977
[Full Text]
Corey, L., Wald, A., Patel, R., Sacks, S. L., Tyring, S. K., Warren, T., Douglas, J. M. Jr., Paavonen, J., Morrow, R. A., Beutner, K. R., Stratchounsky, L. S., Mertz, G., Keene, O. N., Watson, H. A., Tait, D., Vargas-Cortes, M., the Valacyclovir HSV Transmission Study Group,
(2004). Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. NEJM
350: 11-20
[Abstract][Full Text]
Schacker, T. W., Conant, M., Thoming, C., Stanczak, T., Wang, Z., Smith, M.
(2002). Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study. Antimicrob. Agents Chemother.
46: 3243-3248
[Abstract][Full Text]
Mindel, A, Taylor, J, Tideman, R L, Seifert, C, Berry, G, Wagner, K, Page, J, Marks, C, Trudinger, B, Cunningham, A
(2000). Neonatal herpes prevention: a minor public health problem in some communities. Sex. Transm. Infect.
76: 287-291
[Abstract][Full Text]
Ashley, R. L., Wald, A.
(1999). Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology. Clin. Microbiol. Rev.
12: 1-8
[Abstract][Full Text]
Diaz-Mitoma, F., Sibbald, R. G., Shafran, S. D., Boon, R., Saltzman, R. L., for the Collaborative Famciclovir Genital Herpes R,
(1998). Oral Famciclovir for the Suppression of Recurrent Genital Herpes: A Randomized Controlled Trial. JAMA
280: 887-892
[Abstract][Full Text]
Bachman, D. M., Barron, B. A.
(1998). Prevention of Herpes Simplex Keratitis and Iritis. Arch Ophthalmol
116: 259-259
[Full Text]
Kost, R. G., Hill, E. L., Tigges, M., Straus, S. E.
(1993). Recurrent Acyclovir-Resistant Genital Herpes in an Immunocompetent Patient. NEJM
329: 1777-1782
[Full Text]
Dolin, R
(1985). Antiviral chemotherapy and chemoprophylaxis. Science
227: 1296-1303
[Abstract]
Previous
